Background and Objectives
Viral warts are benign proliferative skin lesions caused by the human papillomavirus (HPV) and are contagious among humans. Currently, there are no effective treatments to address the high recurrence rate of viral warts, presenting challenges in achieving their complete eradication. The aim of this study was to evaluate the efficacy and safety of curettage combined with 5-aminolevulinic acid photodynamic therapy (ALA-PDT) for the treatment of recalcitrant acral warts.
Methods
Our study was carried out between July 2023 to June 2025, and the clinical data of 50 patients diagnosed with acral warts were retrospectively collected. Patients were assigned to the curettage group (n = 24) or the combination group (n = 26) based on whether they received photodynamic therapy after curettage. The clinical response effects, recurrence rate and adverse reactions of the two groups were observed and compared.
Results
The cure rate in the combination group was 80.8% (21/26), which was significantly higher than 45.8% (11/24) in curettage group. The recurrence rate in the combination group was 19.2% (5/26), which was lower than 54.2% (13/24) in curettage group (P < 0.05). After three months of follow-up, moderate pain was the main adverse reaction in both groups, and no systemic adverse reactions were observed.
Conclusion
Our results suggest that curettage combined with ALA-PDT is promising as a safe and effective therapy for patients with recalcitrant acral warts.
扫码关注我们
求助内容:
应助结果提醒方式:
